Core binding factor at the crossroads: Determining the fate of the HSC

Journal of Cellular Physiology

Volumn 222, Issue 1, 2010, Pages 50-56

  Link, Kevin A ^a   Chou, Fu Sheng ^a   Mulloy, James C ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR; HYBRID PROTEIN; REPRESSOR PROTEIN; REPRESSOR PROTEIN ETO; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BINDING AFFINITY; BONE MARROW; CELL DIFFERENTIATION; CELL DISRUPTION; CELL FATE; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; DIMERIZATION; EMBRYONIC STEM CELL; GENE DELETION; GENE EXPRESSION; GENETIC ANALYSIS; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY;

ANIMALS; CELL LINEAGE; CELL PROLIFERATION; CORE BINDING FACTORS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; REPRESSOR PROTEINS;

MUS;

EID: 73949157161     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21950     Document Type: Short Survey

References (81)

1. Adya N, Stacy T, Speck NA, Liu PP. 1998. The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates. Mol Cell Biol 18:7432-7443.
2. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. 1996. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 87:2162-2170.
3. Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N, Downing JR, Meyers S, Hiebert SW. 2001. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 21:6470-6483.
4. Berg T, Fliegauf M, Burger J, Staege MS, Liu S, Martinez N, Heidenreich O, Burdach S, Haferlach T, Werner MH, Lubbert M. 2008. Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO. Haematologica 93:1728-1733.
5. Bernasconi P. 2008. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: Relationships and distinctions - A review. Br J Haematol 142:695-708.
6. Cammenga J, Niebuhr B, Horn S, Bergholz U, Putz G, Buchholz F, Lohler J, Stocking C. 2007. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation. Cancer Res 67:537-545.
7. Castilla LH, Wijmenga C, Wang Q, Stacy T, Speck NA, Eckhaus M, Marín-Padilla M, Collins FS, Wynshaw-Boris A, Liu PP. 1996. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 87:687-696.
8. Chen MJ, Yokomizo T, Zeigler BM, Dzierzak E, Speck N. 2009. Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature. 457:887-891.
9. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M, Scadden DT. 2000. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 287:1804-1808.
10. Davis JN, McGhee L, Meyers S. 2003. The ETO (MTG8) gene family. Gene 303:1-10.
11. de Guzman CG, Warren AJ, Zhang Z, Gartland L, Erickson P, Drabkin H, Hiebert SW, Klug CA. 2002. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 22:5506-5517.
12. Durst KL, Lutterbach B, Kummalue T, Friedman AD, Hiebert SW. 2003. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol Cell Biol 23:607-619.
13. Fenske TS, Pengue G, Mathews V, Hanson PT, Hamm SE, Riaz N, Graubert TA. 2004. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Proc Natl Acad Sci USA 101:15184-15189.
14. Gardini A, Cesaroni M, Luzi L, Okumura A, Biggs J, Minardi S, Venturini E, Zhang D, Pelicci P, Alcalay M, Cheung V. 2008. AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets. PLoS Genet 4:e1000275.
15. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. 1998. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18:7185-7191.
16. Goyama S. 2004. The transcriptionally active form of AML1 is required for hematopoietic rescue of the AML1-deficient embryonic para-aortic splanchnopleural (P-Sp) region. Blood 104:3558-3564.
17. Growney JD, Shigematsu H, Li Z, Lee BH, Adelsperger J, Rowan R, Curley DP, Kutok JL, Akashi K, Williams IR, Speck NA, Gilliland DG. 2005. Loss of Runx1 perturbs adult hematopoiesis and is associated with amyeloproliferative phenotype. Blood 106:494-504.
18. Harada Y, Harada H. 2009. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations. J Cell Physiol 220:16-20.
19. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. 2002. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1:63-74.
20. Huang G, Shigesada K, Wee HJ, Liu PP, Osato M, Ito Y. 2004. Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera. Blood 103:3200-3207.
21. Huang G, Zhang P, Hirai H, Elf S, Yan X, Chen Z, Koschmieder S, Okuno Y, Dayaram T, Growney JD, Shivdasani RA, Gilliland DG, Speck NA, Nimer SD, Tenen DG. 2008. PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet 40:51-60.
22. Hug BA, Lee SY, Kinsler EL, Zhang J, Lazar MA. 2002. Cooperative function of Aml1-ETO corepressor recruitment domains in the expansion of primary bone marrow cells. Cancer Res 62:2906-2912.
23. Ichikawa M, Asai T, Saito T, Yamamoto G, Seo S, Yamazaki I, Yamagata T, Mitani K, Chiba S, Hirai H, Ogawa S, Kurokawa M. 2004. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 10:299-304.
24. Ichikawa M, Goyama S, Asai T, Kawazu M, Nakagawa M, Takeshita M, Chiba S, Ogawa S, Kurokawa M. 2008. AML1/Runx1 negatively regulates quiescent hematopoietic stem cells in adult hematopoiesis. J Immunol 180:4402-4408.
25. Kanno Y, Kanno T, Sakakura C, Bae SC, Ito Y. 1998. Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation. Mol Cell Biol 18:4252-4261.
26. Krejci O, Wunderlich M, Geiger H, Chou FS, Schleimer D, Jansen M, Andreassen PR, Mulloy JC. 2008. p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. Blood 111:2190-2199.
27. Kummalue T, Lou J, Friedman AD. 2002. Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein. Mol Cell Biol 22:8278-8291.
28. Kuo YH, Landrette SF, Heilman SA, Perrat PN, Garrett L, Liu PP, Le Beau MM, Kogan S, Castilla LH. 2006. Cbf beta-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia. Cancer Cell 9:57-68.
29. Kwok C, Zeisig BB, Qiu J, Dong S, So CW. 2009. Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes. Proc Natl Acad Sci USA 106:2853-2858.
30. Lancrin C, Sroczynska P, Stephenson C, Allen T, Kouskoff V, Lacaud G. 2009. The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. Nature 457:892-895.
31. Licht JD. 2001. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 20:5660-5679.
32. Liu Y, Cheney MD, Gaudet JJ, Chruszcz M, Lukasik SM, Sugiyama D, Lary J, Cole J, Dauter Z, Minor W, Speck NA, Bushweller JH. 2006. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell 9:249-260.
33. Liu Y, Chen W, Gaudet J, Cheney M, Roudaia L, Cierpicki T, Klet R, Hartman K, Laue T, Speck N. 2007. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. Cancer Cell 11:483-497.
34. Look A. 1997. Oncogenic transcription factors in the human acute leukemias. Science 278:1059-1064.
35. Lorsbach RB, Moore J, Ang SO, Sun W, Lenny N, Downing JR. 2004. Role of RUNX1 in adult hematopoiesis: Analysis of RUNX1-IRES-GFP knock-in mice reveals differential lineage expression. Blood 103:2522-2529.
36. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW. 1998. ETO, a target of t(8;21) in acute leukemia, interacts with theN-CoR and mSin3 corepressors. Mol Cell Biol 18:7176-7184.
37. Lutterbach B, Westendorf JJ, Linggi B, Isaac S, Seto E, Hiebert SW. 2000. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem 275:651-656.
38. Massari ME, Murre C. 2000. Helix-loop-helix proteins: Regulators of transcription in eucaryotic organisms. Mol Cell Biol 20:429-440.
39. Matsunaga T, Kato T, Miyazaki H, Ogawa M. 1998. Thrombopoietin promotes the survival of murine hematopoietic long-term reconstituting cells: Comparison with the effects of FLT3/FLK-2 ligand and interleukin-6. Blood 92:452-461.
40. Miller J, Horner A, Stacy T, Lowrey C, Lian JB, Stein G, Nuckolls GH, Speck NA. 2002. The core-binding factor beta subunit is required for bone formation and hematopoietic maturation. Nat Genet 32:645-649.
41. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. 2002. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 99:15-23.
42. Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, Comenzo RL, Jhanwar S, Moore MA, Nimer SD. 2003. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood 102:4369-4376.
43. Naoe Y, Setoguchi R, Akiyama K, Muroi S, Kuroda M, Hatam F, Littman DR, Taniuchi I. 2007. Repression of interleukin-4 in T helper type 1 cells by Runx/Cbf beta binding to the Il4 silencer. J Exp Med 204:1749-1755.
44. Nishimura M, Fukushima-Nakase Y, Fujita Y, Nakao M, Toda S, Kitamura N, Abe T, Okuda T. 2004. VWRPY motif-dependent and -independent roles of AML1/Runx1 transcription factor in murine hematopoietic development. Blood 103:562-570.
45. North T, Gu TL, Stacy T, Wang Q, Howard L, Binder M, Marín-Padilla M, Speck NA. 1999. Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. Development 126:2563-2575.
46. North TE, Stacy T, Matheny CJ, Speck NA, de Bruijn MF. 2004. Runx1 is expressed in adult mouse hematopoietic stem cells and differentiating myeloid and lymphoid cells, but not in maturing erythroid cells. Stem Cells 22:158-168.
47. North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, Weber GJ, Bowman TV, Jang IH, Grosser T, Fitzgerald GA, Daley GQ, Orkin SH, Zon LI. 2007. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 447:1007-1011.
48. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. 1996. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330.
49. Okuda T, Cai Z, Yang S, Lenny N, Lyu CJ, van Deursen JM, Harada H, Downing JR. 1998. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 91:3134-3143.
50. Okuda T, Takeda K, Fujita Y, Nishimura M, Yagyu S, Yoshida M, Akira S, Downing JR, Abe T. 2000. Biological characteristics of the leukemia-associated transcriptional factor AML1 disclosed by hematopoietic rescue of AML1-deficient embryonic stem cells by using a knock-in strategy. Mol Cell Biol 20:319-328.
51. Okumura A, Peterson LF, Okumura F, Boyapati A, Zhang D. 2008. t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression. Blood 112:1392-1401.
52. Orkin S, Zon L. 2008. Hematopoiesis: An evolving paradigm for stem cell biology. Cell 132:631-644.
53. Park S, Chen W, Cierpicki T, Tonelli M, Cai X, Speck NA, Bushweller JH. 2009. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity. Blood. 113:3558-3567.
54. Peterson L, Yan M, Zhang D. 2007. The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood 109:4392-4398.
55. Putz G, Rosner A, Nuesslein I, Schmitz N, Buchholz F. 2006. AML1 deletion in adult mice causes splenomegaly and lymphomas. Oncogene 25:929-939.
56. Roudaia L, Cheney MD, Manuylova E, Chen W, Morrow M, Park S, Lee CT, Kaur P, Williams O, Bushweller JH, Speck NA. 2009. CBFbeta is critical for AML1-ETO and TEL-AML1 activity. Blood 113:3070-3079.
57. Sasaki K, Yagi H, Bronson RT, Tominaga K, Matsunashi T, Deguchi K, Tani Y, Kishimoto T, Komori T. 1996. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. Proc Natl Acad Sci USA 93:12359-12363.
58. Satoh Y, Matsumura I, Tanaka H, Ezoe S, Fukushima K, Tokunaga M, Yasumi M, Shibayama H, Mizuki M, Era T, Okuda T, Kanakura Y. 2008. AML1/RUNX1 Works as a Negative Regulator of c-Mpl in Hematopoietic Stem Cells. J Biol Chem 283:30045-30056.
59. SunW, Downing JR. 2004. Haploinsufficiency of AML1 results in a decrease in the number of LTR-HSCs while simultaneously inducing an increase in more mature progenitors. Blood 104:3565-3572.
60. Talebian L, Li Z, Guo Y, Gaudet J, Speck ME, Sugiyama D, Kaur P, Pear WS, Maillard I, Speck NA. 2007. T-lymphoid, megakaryocyte, and granulocyte development are sensitive to decreases in CBFbeta dosage. Blood 109:11-21.
61. Taniuchi I, Osato M, Egawa T, Sunshine MJ, Bae SC, Komori T, Ito Y, Littman DR. 2002. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 111:621-633.
62. Tonks A, Pearn L, Tonks AJ, Pearce L, Hoy T, Phillips S, Fisher J, Downing JR, Burnett AK, Darley RL. 2003. The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 101:624-632.
63. van Os R, Kamminga LM, Ausema A, Bystrykh LV, Draijer DP, van Pelt K, Dontje B, de Haan G. 2007. A limited role for p21Cip1/Waf1 in maintaining normal hematopoietic stem cell functioning. Stem Cells 25:836-843.
64. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D, Ronchini C, Ronzoni S, Muradore I, Monestiroli S, Gobbi A, Alcalay M, Minucci S, Pelicci P. 2009. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 457:51-56.
65. Wang Q, Stacy T, Binder M, Marín-Padilla M, Sharpe AH, Speck NA. 1996a. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 93:3444-3449.
66. Wang Q, Stacy T, Miller JD, Lewis AF, Gu TL, Huang X, Bushweller JH, Bories JC, Alt FW, Ryan G, Liu PP, Wynshaw-Boris A, Binder M, Marín-Padilla M, Sharpe AH, Speck NA. 1996b. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell 87:697-708.
67. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. 1998. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 95:10860-10865.
68. Watanabe-Okochi N, Kitaura J, Ono R, Harada H, Harada Y, Komeno Y, Nakajima H, Nosaka T, Inaba T, Kitamura T. 2008. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 111:4297-4308.
69. Wee HJ, Voon DC, Bae SC, Ito Y. 2008. PEBP2-beta/CBF-beta-dependent phosphorylationof RUNX1 and p300 by HIPK2: Implications for leukemogenesis. Blood 112:3777-3787.
70. Wijmenga C, Gregory PE, Hajra A, Schröck E, Ried T, Eils R, Liu PP, Collins FS. 1996. Core binding factor beta-smooth muscle myosin heavy chain chimeric protein involved in acute myeloid leukemia forms unusual nuclear rod-like structures in transformed NIH 3T3 cells. Proc Natl Acad Sci USA 93:1630-1635.
71. Wildonger J, Mann RS. 2005. The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor. Development 132:2263-2272.
72. Wunderlich M, Krejci O, Wei J, Mulloy JC. 2006. Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability. Blood 108:1690-1697.
73. Yan M, Burel SA, Peterson LF, Kanbe E, Iwasaki H, Boyapati A, Hines R, Akashi K, Zhang DE. 2004. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci USA 101:17186-17191.
74. Yan M, Kanbe E, Peterson L, Boyapati A, Miao Y, Wang Y, Chen I, Chen Z, Rowley J, Willman C, Zhang D. 2006. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 12:945-949.
75. Yan M, Ahn EY, Hiebert SW, Zhang D. 2009. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis. Blood 113:883-886.
76. Yeh JR, Munson KM, Elagib KE, Goldfarb AN, Sweetser DA, Peterson RT. 2009. Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nat Chem Biol 5:236-243.
77. Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, Binder M, Maŕn-Padilla M, Tenen DG, Speck NA, Zhang DE. 1997. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 15:303-306.
78. Yoshihara H. 2007. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 1:685-697.
79. Zhang J, Hug BA, Huang EY, Chen CW, Gelmetti V, Maccarana M, Minucci S, Pelicci PG, Lazar MA. 2001. Oligomerization of ETO is obligatory for corepressor interaction. Mol Cell Biol 21:156-163.
80. Zhang J, Kalkum M, Yamamura S, Chait BT, Roeder RG. 2004. E protein silencing by the leukemogenic AML1-ETO fusion protein. Science 305:1286-1289.
81. Zhao L, Cannons JL, Anderson S, Kirby M, Xu L, Castilla LH, Schwartzberg PL, Bosselut R, Liu P. 2007. CBFB-MYH11 hinders early T-cell development and induces massive cell death in the thymus. Blood 109:3432-3440.